CROSS-10-YEAR
Regimen
- Experimental
- neoadjuvant CROSS (carboplatin + paclitaxel + 41.4 Gy RT) + surgery
- Control
- surgery alone
Population
Clinically resectable locally advanced esophageal or GEJ cancer (both SCC and adenocarcinoma), 10-year follow-up
Key finding
10y OS 38% (nCRT+surgery) vs 25% (surgery alone); absolute benefit 13%. Cancer-specific death HR 0.60. Locoregional relapse HR 0.40.
Source: PMID 33891478